Article thumbnail

SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis

By Robert T. Jacobs, Bakela Nare, Stephen A. Wring, Matthew D. Orr, Daitao Chen, Jessica M. Sligar, Matthew X. Jenks, Robert A. Noe, Tana S. Bowling, Luke T. Mercer, Cindy Rewerts, Eric Gaukel, Jennifer Owens, Robin Parham, Ryan Randolph, Beth Beaudet, Cyrus J. Bacchi, Nigel Yarlett, Jacob J. Plattner, Yvonne Freund, Charles Ding, Tsutomu Akama, Y.-K. Zhang, Reto Brun, Marcel Kaiser, Ivan Scandale and Robert Don


Human African trypanosomiasis (HAT) is caused by infection with the parasite Trypanosoma brucei and is an important public health problem in sub-Saharan Africa. New, safe, and effective drugs are urgently needed to treat HAT, particularly stage 2 disease where the parasite infects the brain. Existing therapies for HAT have poor safety profiles, difficult treatment regimens, limited effectiveness, and a high cost of goods. Through an integrated drug discovery project, we have discovered and optimized a novel class of boron-containing small molecules, benzoxaboroles, to deliver SCYX-7158, an orally active preclinical drug candidate. SCYX-7158 cured mice infected with T. brucei, both in the blood and in the brain. Extensive pharmacokinetic characterization of SCYX-7158 in rodents and non-human primates supports the potential of this drug candidate for progression to IND-enabling studies in advance of clinical trials for stage 2 HAT

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1998). A comparative review of the pharmacokinetics of boric acid in rodents and humans.
  2. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
  3. (1998). Antitrypanosomal Activity of a New Triazine Derivative, SIPI 1029, In Vitro and in Model Infections.
  4. (2009). Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.
  5. (1997). Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.
  6. (1997). Blood boron concentrations in pregnant rats fed boric acid throughout gestation.
  7. (2005). Chemotherapy of trypanosomiases and leishmaniasis.
  8. (1989). Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers.
  9. (1985). Cultivation in a semi-defined medium of animal infective forms of Trypanosoma
  10. (2010). Discovery of Novel Benzoxaborole-Based Potent Antitrypanosomal Agents.
  11. (2010). Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African Trypanosomiasis.
  12. (1987). Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models.
  13. (2008). Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next?
  14. (2006). Human African trypanosomiasis (sleeping sickness): epidemiological update.
  15. (2007). Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.
  16. (1988). Human drug metabolism in vitro.
  17. (2004). In vitro absorption and secretory quotients: practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates.
  18. (1996). In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors.
  19. (2004). Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.
  20. (1975). Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test.
  21. (2010). NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
  22. (2009). NECT trial: more than a small victory over sleeping sickness.
  23. (2007). Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series.
  24. (2009). Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
  25. (2007). Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
  26. (2010). Nmyristoyltransferase inhibitors as new leads to treat sleeping sickness.
  27. (2003). Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by Pglycoprotein in cell culture models of intestinal epithelium.
  28. (2007). Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery.
  29. (1998). Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.
  30. (2001). Rational use of in vitro P-glycoprotein assays in drug discovery.
  31. (1983). Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes.
  32. (2007). Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
  33. (2010). State of the Art in African Trypanosome Drug Discovery. Curr Top Med Chem.
  34. (2004). Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.
  35. (1997). The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro.
  36. (2008). The Burden of Human African Trypanosomiasis.
  37. (1999). Therapy of human African trypanosomiasis: current situation.
  38. (2008). Traversal of human and animal trypanosomes across the blood-brain barrier.
  39. (2009). Trypanocidal drugs: mechanisms, resistance and new targets.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.